STSA - Satsuma Pharmaceutic...

Terminal Value of Satsuma Pharmaceuticals, Inc.(STSA), Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeu

Satsuma Pharmaceuticals, Inc.

STSA

NASDAQ

Inactive Equity

Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

1.1 USD

0 (0%)

Overview Profile Financial Statements Financial Ratios Chart Analysis News Corporate Actions DCF

Operating Data Balance Sheet Free Cash Flow Free Cash Flow Buildup Terminal Value Intrinsic Value WACC

FMP

Home Terms of Service Privacy Policy Blog Contact Us

API

Documentation Pricing Formulas Market Indexes

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.